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Background: Treatment services to patients with substance use disorders (SUDs), including those mandated to
treatment, needs to be evaluated and evidence based. The Norwegian Municipal Health Care Act (NMHCA) calls for
compulsory treatment for persons with “severe and life-threatening substance use disorder” if these individuals are
not otherwise willing to be voluntarily treated and consequently risk their lives over drug use. Mental distress is
known to be high among SUD patients admitted to inpatient treatment. The purpose of this study is to describe
changes in mental distress from admission to a 6-month follow-up in patients with SUDs, which underwent either
voluntary or compulsory treatment.
Method: This prospective study followed 202 hospitalized patients with SUDs who were admitted voluntarily
(VA; n = 137) or compulsorily (CA; n = 65). Levels of mental distress were assessed with SCL-90-R. Of 123
patients followed-up at 6 months, 97 (62 VA and 35 CA) had rated their mental distress at admission,
discharge and follow-up. Sociodemographics and substance use severity were recorded with the use of The
European Addiction Severity Index (EuropASI). We performed a regression analysis to examine factors
associated with changes in psychiatric distress at the 6-month follow-up.
Results: The VA group exhibited higher mental distress than the CA group at admission, but both groups
improved significantly during treatment. At the 6-month follow-up, the VA group continued to show reduced
distress, but the CA group showed increases in mental distress to the levels observed before treatment. The
deterioration appeared to be associated with higher scores that reflected paranoid ideas, somatization,
obsessive-compulsive symptoms, interpersonal sensitivity, and depression. Active substance use during follow-up was
significantly associated with increased mental distress.
Conclusion: In-patient treatment reduces mental distress for both CA and VA patients. The time after discharge seems
critical especially for CA patients regarding active substance use and severe mental distress. A greater focus on
continuing care initiatives to assist the CA patients after discharge is needed to maintain the reduction in mental
distress during treatment. Continuing-care initiatives after discharge should be intensified to assist patients in
maintaining the reduced mental distress achieved with treatment.
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Studies on the general population and clinical samples
have consistently shown that psychiatric comorbidities
are common among patients with substance use disor-
ders (SUDs) [1–3]. Comorbidities have been associated
with frequent psychiatric admissions [4], violence [5],
suicidal behavior [6], poor treatment response [7, 8],
poor long-term prognosis [9], severe impairments and
disabilities [9], and high mortality rates [10], particularly
among adolescents and young adults [9]. SUDs have also
been positively correlated to different types of psychi-
atric disorders, such as depression or agoraphobia, and
to the severity of the disorder [11]. Mental distress, de-
fined as an individual’s level of mental complaints and
symptoms, is frequently used as an outcome measure in
medical and psychological research [12]. In screening for
psychiatric disorders, the concept of mental distress is
widely used. For example, it is estimated that among pa-
tients with SUDs between 30 and 50% suffer from a psy-
chiatric disorder [13]. Other studies have shown that
30–40% of people with alcohol related disorders and 40-
50% of people with other SUDs also have a psychiatric
disorder [14–17]. In particular, patients with SUDs ad-
mitted to in-patient treatment showed even higher levels
of mental distress [11, 18, 19] Overall, a SUD combined
with a comorbid psychiatric disorder can have negative
impacts on different aspects of patient conditions and
functions [20].
Although SUDs are often difficult to cure, treatment
methods are currently available to stabilize patients, re-
duce harm, and improve comorbidity. These effects can
increase life expectancy and quality of life [21]. Trad-
itionally, the goal of SUD treatment has been to achieve
total abstinence, or at least reduced substance use. In
general, reductions in substance use have been associ-
ated with improved outcomes of comorbid disorders
[22]. For a treatment to be perceived as attractive and
relevant to individuals with SUDs, it must provide
worthwhile and rewarding experiences, in terms of re-
ducing mental distress. Hence, treatments must bene-
fit the patient’s perspective. To promote patient
experiences of improvements, treatment services must
be attentive to patient needs in the psychiatric do-
main, and monitor changes in clinically relevant out-
comes throughout the course of treatment and
following treatment [23]. There is consensus that pa-
tients with SUDs that have not responded to less in-
tensive treatment efforts and whose SUDs’ poses an
ongoing threat to their physical and mental health
may require in-patient treatment [24]. Although in-
patients are likely to experience reduced symptoms of
mental distress, due to the controlled environment,
little is known about the stability of symptoms over
time, following discharge. Hence, positive improvementsin mental distress that occur during treatment may not
necessarily persist after discharge.
Voluntary admittance is the first choice and major
gateway for treatment, but in the SUD field, voluntary
admittance may not meet the expected positive out-
comes, and patients may continue with detrimental pat-
terns of substance use. In those circumstances, measures
are available in many countries, including Norway, for
applying compulsory in-patient drug treatment based on
the medical needs of the patient, as opposed to resorting
to legal means to coerce treatment through the criminal
justice system.
The Norwegian Municipal Health Care Act (NMHCA)
sanctions involuntary interventions for adult patients
with SUDs in Norway [25]. The Act covers an option for
retention (up to 3 months), when the health of the pa-
tient is seriously at risk, due to extensive, prolonged sub-
stance use, and when voluntary efforts have proven
insufficient.
Literature reviews regarding compulsory treatment
have generally concluded that research on the efficacy is
inconsistent and inconclusive [26–29]. This is in part be-
cause these literature reviews do not always distinguish
between different forms of compulsory treatment in
conducting their analyses of outcomes. Most of the re-
search and evidence on the effectiveness of compulsory
treatment relates to offenders who are coerced and re-
ferred via the criminal justice system [30]. Among coun-
tries with a distribution of welfare through the state and
in favor of using the civil law, Sweden has provided
some relevant research in the field of patients with SUDs
compulsory admitted to treatment. For example,
Gerdner and Berglund concluded that patients com-
pulsory admitted to SUD treatment have higher re-
tention rates in treatment programs and aftercare,
compared to VA patients. CA patients showed global
outcomes that were as good as, or even better than
those of VA patients[31]. Generally, for patients with
SUDs and co-occurring psychiatric disorders admitted
to treatment, it is particularly important to examine
the outcomes at some point after the initial treatment
episode has ended given that treatment effects may
not have been retained during the follow-up phase
[32]. There is a scarcity of follow-up studies that in-
clude both measures of substance abuse and mental
distress for patients with SUDs [33]. Among patients
with SUDs that underwent compulsory admission (CA),
most studies examined treatment completion, reductions
in substance use and less frequently, improvements in
psychological symptoms [34–36]. Thus, a knowledge gap
exists.
This study aims to: (1) describe the level of mental dis-
tress among a cohort of SUD patients; (2) examine the
change in mental distress during the observation period
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factors associated with change in mental distress at
6-month follow-up.
Methods
Settings and procedures
The Norwegian Social Services Act of 1993 allowed
compulsory admissions to the hospital for persons with
severe and life-threatening substance use. In 2012, this
law was replaced by the NMHCA, §10.2, sanctions in-
voluntary interventions for adult patients with SUDs
[25]. In this manuscript, we followed a similar method-
ology to one used previously [37]. Recruitment for this
prospective study continued consecutively between
January 2009 and May 2011 from three different publicly
funded treatment centres in the south-eastern part of
Norway. The treatment wards had multidisciplinary
staffs, including psychiatrists, psychologists, social
workers, occupational therapists, specialized nurses,
and other trained staff. The centres offered treatment
for patients with a primary SUD, often combined with
mental disorders. Treatment included assessment of
somatic and mental health along with pharmacotherapy,
cognitive milieu therapy, and individual motivation en-
hancement. Before study inclusion, the patients were
detoxified, verified by negative urine tests for alcohol,
opioids, central stimulants (amphetamines, methamphet-
amines, and cocaine), benzodiazepines, and cannabis to
establish baseline values not influenced by withdrawal
symptoms.
No formalized aftercare service was provided by the
wards, but aftercare plans for individuals were made in
collaboration with primary care services in the local mu-
nicipalities; e.g., appointments with social services.
Follow-up interviews were performed 6 months after
discharge from the hospitals and took place between July
2009 and December 2011. Because patients came from
all over the country (particularly the CA group), the pro-
ject staff attempted to contact all patients directly by
phone, mail, or post. In some cases, patients were found
to be in prison or in inpatient treatment institutions and
arrangements were made to meet them there, which in-
cluded extensive travelling for the data collection team
as all the interviews were conducted face to face.
Participants
A total of 326 patients consecutively admitted to sub-
stance use disorder and psychiatry wards were identified
as potentially relevant for this study. Participants were
eligible when they were >18 years of age, had a SUD,
could understand Norwegian, and were admitted at least
3 weeks prior to study inclusion, which allowed them
sufficient time for detoxification and stabilization before
providing informed consent. We verified whether thepatients were detoxified, by negative urine tests for
alcohol, opioids, central stimulants (amphetamines,
methamphetamines, and cocaine), benzodiazepines, and
cannabis; thus, we were able to establish baseline values
that were not influenced by withdrawal symptoms. Ac-
cording to the inclusion criteria, 228 were eligible, but
26 patients refused to participate. Of the 202 patients
enrolled at baseline (65 CA and 137 VA), 123 (61%)
were followed-up at 6 months.
Because of limitations in funding and the large geo-
graphical uptake area, CA patients were prioritized for
follow-up (82% CA patients versus 59% VA patients
were included) because the CA patients were less repre-
sented in the sample at baseline. Thus, the higher loss to
follow-up in the VA group was mainly due to adminis-
trative and logistic reasons. Beyond this, the attrition
analysis showed no other differences between those who
were and were not included at follow-up in terms of
demographic data, severity scores, or length of stay in
the initial treatment episode.
Instruments and measure
The Mini International Neuropsychiatric Interview, ver-
sion 5.0, was conducted at baseline to assess SUD and
other psychiatric diagnosis [38]. For statistical purposes,
psychiatric diagnoses were categorized as Axis I
(symptom disorders) and Axis II (personality disorders).
Common Axis I disorders include anxiety and mood dis-
orders, attention deficit disorders, schizophrenia and
other psychotic disorders.
To assess demographics and severity of substance use
variables, the most commonly used measure within
addiction treatment research was used: The European
Addiction Severity Index (EuropASI) [39, 40]. The
EuropASI is a structured interview performed by trained
and certified staff. The same questionnaire was used at
follow-up. Drug and alcohol use in the 30 days preced-
ing the follow-up interview were evaluated to determine
whether the patients were abstinent or not. Additionally,
time in a controlled environment as defined by the
EuropASI as days in jail or SUD treatment in the 30 days
before follow-up was used to assess differences in en-
gagement with aftercare services. As a proxy for severe
mental distress, we assessed whether patients had ever
had suicidal attempts in their lifetime. Mental distress in
general was measured with the Symptom Checklist-90-R
(SCL-90-R) [41], a widely used inventory used clinically
in Scandinavia to monitor psychological distress both
before and after treatment [42–44]. Additionally, the
SCL-90-R has been tested in a Norwegian population
sample [45]. The SCL-90-R has 90 items rated on a
five-point Likert-type scale, ranging from “not at all”
(0) to “extremely” (4), and includes nine subscales
(somatization, obsessive-compulsive, depression, anxiety,
Table 1 Baseline socio-demographic variables for patients with
SUDs
Variables All patients,
N = 202
Follow-up sample,
N = 123
Mean age, years 30.0 (±8.9) 30.4 (±9.8)
Female 68 (34) 47 (39)
Education, years 10.8 (±1.9) 10.8 (±2.1)a
Relationship status, single 136 (69) b 84 (69)c
Main SUD diagnosis
Alcohol use disorder (AUD) or
AUD + concurrent drug use disorders
34 (17) 20 (16)
Drug use disorder 168 (83) 103 (84)
Psychiatric diagnosis
Axis I disorders 117 (60) 71 (58)
Axis II disorders 9 (4.5) 4 (3)
Axis I and II disorders 24 (12) 16 (13)
Only SUD diagnosis 52 (26) 32 (26)
Severity scores
Injection use 105 (54) d 71 (60)e
Duration of most problematic
substance use, years
11.1 (±7.6) 11.6 (±7.6)f
Time in treatment, days 57 (26) 58 (26)
Suicidal attempts – lifetime
prevalence
94 (49) g 60 (51)h
Compulsory admission 65 (32) 51 (42)
SCL-90-R GSI, mean (SD) 1.2 (±0.70)i 1.2 (±0.74)j
Values represent the numbers of patients (%) or mean (±SD); in some cases,
the total number of patients changed, as follows: aN = 117; b N = 198; cN = 121;
dN = 195; eN = 119; fN = 117; gN = 191; hN = 117; iN = 197, jN = 120
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ideation, and psychoticism). The present study uses the
Global Severity Index (GSI), which is the average rating of
all 90 items. GSI is often used as an overall index of dis-
tress in studies of substance dependent samples [46]; the
higher the score, the greater the distress [47]. A score of
GSI > 1 is considered to be a pathological score. Changes
in mental distress were computed by subtracting the GSI
determined at follow-up from the GSI determined at ad-
mission, hereafter called the ‘GSI change’. Thus, a ‘positive
score change’ refers to an improved mental distress. For
this study, we chose to include only the participants that
provided complete dataset on the outcome variable, men-
tal distress.
Analysis and statistical methods
Descriptive statistics were used to elaborate baseline
characteristics. To examine the change in psychiatric
distress between discharge and the 6-month follow-up,
we used the paired sample t-test, for both CA and VA
groups. Linear regression was used to examine predic-
tors of changes in psychiatric distress, from baseline to
the 6-month follow-up. Preliminary bivariate analyses
were first undertaken. Variables with seemingly little in-
fluence on the dependent variable (p-value >0.20) were
not included in the multiple regression (adjusted model),
as recommended by Altman [48]. We also controlled for
gender and age. The final multiple regression model
used simultaneous entry of variables (the “enter”
method). Results are presented as unstandardized beta
coefficients with 95% confidence intervals (CIs). P-
values < 0.05 were considered statistically significant.
Analyses were performed with SPSS 21.0 Software (SPSS
Inc., Chicago, IL, USA).
Results
At baseline, the 202 participants had a mean age of
30 years, and 34% were women (Table 1). Among these,
32% (N = 65) had undergone CA and 68% (N = 137) were
VA. All patients met the ICD-10 criteria for SUDs; the
majority had a drug use disorder (83%). Use of an
injected drug 6 months prior to hospitalization was re-
ported by 54% of participants. The mean SCL-90 GSI
for our cohort, at baseline, was 1.2, which is 0.2 above
the pathological cut off used as a general measure of
psychopathology at the group level. In our cohort,
56% of patients had scores above the pathological
cut-off. The burden of mental distress was higher in
the VA group than in the CA group, mean difference
(MD) = 0.34, t(95) = 2.34, p < 0.02, CI: 0.053-0.632, but
distress improved at similar magnitudes between groups
during treatment (Fig. 1). At the end of treatment, the ma-
jority of patients (67%) had reduced their mental distress
scores to below the clinical cut-off for pathology. Of the123 patients followed-up at 6-months, 97 (35 in the CA
group and 62 in the VA group) had rated their mental dis-
tress at all three time points (at admission, discharge, and
the 6-month follow-up); these were included in the
follow-up analyses. An attrition analysis showed no other
differences between those who completed the SCL-90-R
interview and those who did not, in terms of demographic
data, severity scores, or levels of mental distress.
At the 6-month follow-up, the mental distress in the
CA group had deteriorated to a level similar to that ob-
served before treatment. In contrast, the VA group
retained the improvement achieved during treatment
throughout the follow-up (Fig. 1). The negative devel-
opment in mental distress in the CA group seemed
to arise mainly from increases in the following sub-
scales: somatization (MD= 0.37, t(34) = -3.17, p = 0.003),
obsessive-compulsive symptoms (MD= 0.26, t(34) 0 -2.91,
p = 0.006), interpersonal sensitivity (MD = 0.23, t (34) 0
-2.16, p = 0.038), depression (MD = 0.33, t(34) = -3.13,
p = 0.004), and paranoia (MD= 0.4, t(34) = -3.01, p = 0.005)
(Fig. 2). For the sample as a whole, there was an overall de-
crease in mental distress from admission to follow-up
Fig. 1 Changes in mental distress from baseline to 6-month follow-up in patients treated for substance use disorders. Notes: T1 = baseline,
T2 = discharge, T3 = follow-up at 6 months. Red line: changes in mental distress in voluntary admission group. Blue line: changes in
mental distress in compulsory admission group. Mental distress was measured with the Global Score Index (GSI) of the Symptoms Checklist (SCL-90-R).
* P value <0.01
Fig. 2 Changes in mental distress domainsa from discharge to the 6-month follow-up in patients treated for SUDsb. Notes: Red: the voluntary
admission group; blue: the compulsory admission group. *p < 0.05 (paired t-test). aMental domains are subscores that correspond to the nine
dimensions of the Symptoms Checklist (SCL-90-R). b Changes in mental distress were computed by subtracting the GSI determined at follow-up
from the GSI determined at discharge; a ‘positive score change’ refers to an improvement in mental distress Abbreviations: SUD = substance use
disorder, SOM = somatization, OBS = obsessive-compulsion, INT = interpersonal sensitivity, DEPR = depression, ANX = anxiety, HOST = hostility,
PHOB = phobic anxiety, PARA = paranoid ideation, PSY = psychoticism, GSI = global score index
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main contribution came from the progress achieved in the
VA group (Fig. 1).
Preliminary bivariate regression analysis showed that
there were no strong association (p-value >0.2) between
partnerships, education, injection use the last 6 months,
days in controlled environment, and changes in GSI
from baseline to follow-up. These variables were not
retained in multiple regression analysis. We found that
only abstinence was a significant predictor for changes
in GSI in the final adjusted model (β = 0.26, 95% CI
0.06–0.51; Table 2). Descriptively, 41% of the sample (40
of 97 patients) reported abstinence at follow-up; those
that reported non-abstinence had only a minimal GSI
improvement (0.04); in contrast, those that reported ab-
stinence had a considerable GSI improvement of 0.58.
Discussion
In the present study, the majority of in-patients with
SUDs had mental distress levels above the clinical cut-
off at baseline, but they improved during treatment. At
the 6-month follow-up, the level of mental distress in
the CA group returned to the level observed prior to
treatment, but the VA group retained the improvement
achieved with treatment. A multiple linear analysis iden-
tified active drug use as the only variable that could pre-
dict increased levels of mental distress at follow-up.
At baseline, the levels of mental distress were higher
among patients in the VA group than among those in
the CA group. However, the markedly elevated mental
distress levels we observed among all patients with SUDs
at admission confirmed findings from previous studies
that showed that patients with SUDs experienced high
level of mental distress compared to the general popula-
tion [11]. This observation was also reported in a studyTable 2 Predictors of changes in mental distress in patients
with SUDs at follow-up (N = 97)a
Predictor Beta (95% CI)b P-value
Socio-demographic variables
Gender (female) 0.10 (-0.22/0.340) 0.561
Age, years -0.01 (-0.04/0.01) 0.248
Compulsory admission -0.28 (-0.60/0.05) 0.100
Duration of most problematic substance
use, years
0.02 (-0.01/0.05) 0.110
Follow-up variables
Abstinence in the last 30 days of follow-up 0.49 (0.18/0.80) 0.002
a Mental distress was measured with the Global Score Index (GSI) of the
Symptoms Checklist (SCL-90-R). Changes in mental distress were computed by
subtracting the GSI determined at follow-up from the GSI determined at
admission; a ‘positive score change’ refers to an improvement in mental distress
b Unstandardized beta coefficient with 95% Confidence Interval (CI) and
R2 = 0.1, derived from a multiple linear regression with simultaneous entry of
variables (the "enter" method)that included patients legally coerced into treatment;
moreover, patients in the coerced group had higher sub-
stance use severity and less mental distress than patients
in the VA group, similar to our findings [34]. The high
level of mental distress among patients in the VA group
might have been an important motivating factor for vol-
untarily seeking treatment, as suggested in previous
studies [49, 50]. Our findings indicated that compulsory
treatment was primarily applied due to the severity of
substance use, and not because of the severity of psy-
chiatric symptoms. This finding appeared to be con-
sistent with the NMHCA, a special law that governs
treatment for patients with severe or life-threatening
SUD conditions.
Our study showed that, after discharge, patients in the
CA and VA groups followed divergent trajectories of
mental distress. The VA group maintained reduced men-
tal distress at the 6-month follow-up; this outcome was
more positive than the outcomes previously reported in
comparable studies [51]. In contrast, the CA group
showed increases in depression, obsessive-compulsive
symptoms, paranoia, somatization, and interpersonal
sensitivity. This outcome appeared to have resulted from
a relapse to drug use on a group level. This could sug-
gest that those who sought treatment voluntarily may
have been motivated and ready to make changes in
substance use whereas those who were compulsorily
admitted may not to the same extent have seen their
drug use as a problem or were not ready to consider
reducing use. This might highlight the need for extra
supports to build motivation toward change within
the CA group (both during the inpatient stay and as
part of aftercare).
Patients that used injected drugs exhibited higher rates
of mental distress, consistent with previous findings
[52]. This finding suggested that the severity of a SUD
was related to the level of mental distress. A previous
paper reported improved 6-month follow-up SUD out-
comes of the present study (frequency of substance use,
injection use, and overdoses), but improved outcomes
were reported significantly more frequently in the VA
than in the CA group (e.g., 61% versus 37% reported re-
duction in the frequency of the preferred substance)
[37]. The present paper elaborate on these findings; pa-
tients that remained abstinent were more likely to show
lower levels of mental distress than patients that re-
lapsed at 6 month follow-up.. In accordance with other
studies [53, 54], our findings implied that patients that
actively used drugs were less likely to retain the im-
provement in mental distress achieved with treatment;
this finding highlighted the complex nature of mental
distress in patients with SUDs. Epidemiological studies
on the general population have shown that there are bi-
directional influences between SUDs and psychiatric
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each other [15].
In light of the limited formalized care after discharge,
it is possible that the inpatient-period alone was insuffi-
cient to establish long-term abstinence. Considering that
the models for case management share the same core el-
ements: assessment, planning, linkage and monitoring
[55, 56], it may be worth noticing that an alternative
may include specifically designed approaches for CA pa-
tients based on the assumption that they may be am-
bivalent about change such as for example enhanced use
of motivational interview in the monitoring phase.
A continuum of care that included after-discharge care
was previously demonstrated to be supportive in retain-
ing improvements up to follow-up among patients that
underwent CA [56].
Our findings suggested that both providers and pro-
grams should be available to provide assessments and
management of co-existing psychological problems. This
initiative should be built into the care period after dis-
charge. Stand-alone interventions should not be consid-
ered adequate treatment for individuals with severe
SUDs [57].
In the acute phase of CA treatment, the main goal is
to provide life-saving treatment; however, in the longer
term, the aim is to reduce drug use and increase the mo-
tivation for further treatment, preferably voluntary treat-
ment, which can lead to long-term recovery [58]. The
NMHCA does seem to fulfil its aim of reaching patients
with severe SUDs. To obtain maximum long-term bene-
fits for patients that undergo CA, the in-patient treat-
ment should be more integrated into the broader
treatment system. Accordingly, from our standpoint, a
key factor for achieving maximum benefit is to achieve
better coordination between the various care services;
and in our case, this factor is particularly important dur-
ing the transition to care after discharge. For example,
this can be achieved by a case management-based ap-
proach [59].
Methodological considerations
The strength of this study was its prospective design,
which allowed the examination of psychiatric distress
over time; i.e., the 6 months following discharge from
SUD treatment. However, caution should be taken in
generalizing these findings, because there was a high-
attrition rate at follow-up. In addition, this study was
based on self-reported data. Although the dataset is
largely representative of hospitalized SUD populations in
Norway, some data, particularly the outcomes in the CA
group, may vary considerably across settings and regions
with different laws regarding compulsory SUD treatment
outside of Norway. Although longitudinal studies like
this can enhance causal inference it cannot eliminatecompeting explanations and, as a result, does not estab-
lish a causal relationship.
Conclusions
This study profiled the mental distress in two types of
patients treated for SUDs. One type of patient was ad-
mitted voluntarily. These patients had high levels of
mental distress at baseline, which improved during treat-
ment; moreover, this improvement was maintained at
the 6-month follow-up. The other type of patient under-
went compulsory treatment. These patients had lower
mental distress than the patients voluntarily admitted,
but they also showed improvements with treatment;
however, in the CA group, the levels of mental distress
had returned to baseline at the 6-month follow-up.
Our study found that active substance use was the sole
predictive factor of negative change in mental distress in
patients with SUDs at the 6-month follow-up visit. This
finding highlighted the importance of abstinence as a
treatment goal for individuals with severe SUDs, also in
order to maintain mental health stability.
This study also highlighted the need to employ a
broader range of after-discharge interventions to prevent
relapses and accompanying increases in mental distress
for patients that undergo CA. In addition to the for-
malized treatment options available, clinicians may
recommend that patients seek abstinence-supportive
help, for example, from peer-based groups [60], to
maintain improvements in mental distress achieved
during treatment.
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